Hydreight Technologies (TSXV:NURS, OTCQB:HYDTF)’s Post

#Casestudy: Advancing Bioequivalence for Type-2 Diabetes and Weight management. Our latest research evaluates the bioequivalence of an injectable for Type 2 diabetes and weight management, crucial for ensuring consistent therapeutic outcomes. This research aims to ensure that new formulations match the safety and efficacy of existing therapies, offering patients reliable and effective treatment options. Read more about how these advancements contribute to better healthcare solutions and improved patient outcomes. #Type2Diabetes #WeightManagement #Bioequivalence #SyngeneResearch   

#DoseofInsight: Deconstructing Pharmacy with Dr. Jeff Eichholz, PharmD. What’s happening? Read about the launch of #LillyDirect and how it will affect access to weight loss, migraine and diabetes medications like #Zepbound, #Wegovy and #Ozempic. What's next? Review coverage intent of weight loss medications as well as Utilization Management programs available for CGRP inhibitors and all GLP-1s (diabetic and weight loss). #MuchBetterAtMB

"🌐 Transforming the landscape of diabetes diagnostics, the H8-HBA1C Analyser stands at the forefront of innovation. Experience a paradigm shift in precision and efficiency, as this cutting-edge technology 🚀 redefines the way we monitor HbA1c levels. Our analyser goes beyond the conventional, offering swift and accurate results ⏱, saving valuable time for healthcare professionals and ensuring a seamless experience for patients. With advanced features that minimize interference from common hemoglobin variants, we've prioritized specificity to provide trustworthy insights for effective diabetes management. 📞 Call us right away on: 9444406059 and embark on the journey towards advanced and efficient diabetes care.  " https://shorturl.at/belr5 #clinicalautomationservices #HBA1CAnalyzer #H8Analyzer #medicaldiagnostics #medicaldiagnosis #medigaldiagnosticequipment #diagnostic #diagnostics #diagnosis #diagnostictools #diagnose #diagnosticequipment #biochemistry

Today we announce the launch of GlucoseReady™, an integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools including disease specific electronic clinical outcomes assessments (eCOA), behavioral assessment by the SPUR™ tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy. Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance. Unique compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance.   Together, GlucoseReady™ provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform. It is specifically designed for user friendliness, patient and site support, as well as the requirements of an FDA inspection. https://lnkd.in/e2Df6A9p   Learn more at our webinar on May 7: https://lnkd.in/eRfdjcpH     #GlucoseReady #Innovation #ClinicalTrials #CardiometabolicDisease #DigitalHealth #Clinicalink

If you have an upcoming diabetes trial and would like the hypoglycemic event to trigger an ePRO and then have access to this insight in near real time, please do reach out to us to learn more about GlucoseReady!

Exciting news today with the official launch of GlucoseReady! An example of true innovation. The GlucoseReady platform with CGM, BGM, weight scales, actigraphy, behavioral assessment, eCOA, Sensors and Wearables was matured in response to the May 2023 FDA guidelines which addresses the potential to include hypoglycemia as an endpoint as well as utilize Continuous Glucose Monitoring (CGM) to characterize glycemia and detect hypoglycemia. This requires not only real time data, but the ability to in-trial act on real time data. With GlucoseReady, CGM data is captured directly into the Clinical ink cloud. GCM based detection of hypoglycemic events trigger ePROs like hypoforms at the time of the event and provide a clear feedback loop to patients to contextualize CGM events when they occur and with structured ascertainment of patient’s symptomatology. Hope to see you on the Webinar on 7th May. https://lnkd.in/eRfdjcpH

The 2-year results from the #RheOx Feasibility Study are published! The single-arm study using #BronchialRheoplasty for patients with #ChronicBronchitis demonstrated statistically significant improvements in health-related quality of life at 2 years.* The COPD Assessment Test (CAT) and St. George’s Respiratory Questionnaire (SGRG) scores improved by 5.6 and 11.8 points, respectively. A reduction in moderate and severe COPD exacerbations was also observed compared to the year prior to treatment.** To view the publication, visit https://bit.ly/428LOJQ. To learn more about the #RheOx system, visit https://lnkd.in/gFiKHkw3. #CB #COPD #Bronchitis #PEF #MedEd #interventionalpulmonology *Sample size: 17 patients **Sciurba FC, Dransfield MT, Kim V, et al. Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOx. BMJ Open Respir Res 2023;10:e001710. doi:10.1136/bmjresp-2023-001710 The RheOx® system is an investigational device in the United States and is limited by Federal (or United States) law to investigational use.

Another PAH Therapy, But Will Needy Patients Have Access? J&J adds to the options for pulmonary arterial hypertension treatments. But will patients who need assistance be able to access this or other therapies? A review of the relevant patient assistance foundations gives reason for concern. The Disease: A rare, genetic disease that is often fatal within 2 years of diagnosis, if not treated, PAH creates dangerously high blood pressure in the arteries of a patient’s lungs. PAH makes it difficult for blood to flow through the lungs, complicating oxygen exchange. The heart works harder and harder trying to pump blood through the compromised arteries. The heart muscles thicken under the strain, and eventually the heart goes into failure. Good News and Bad News: The good news is that there are highly effective drug therapies that can prolong patients’ lives for decades. The bad news is that needy patients, facing high co-insurance obligations, have insurance “coverage”, but no meaningful access in reality. Is There Hope?: There is. Co-payment charity foundations can provide assistance to patients that meet their financial eligibility requirements. But there’s a problem. If someone you cared about was diagnosed today with PAH, 75% of the foundation funds for the disease are closed and aren’t providing any assistance. It’s March. Funds tend to receive most of their support commitments in December and then must manage those funds to cover patient needs over the course of the calendar year. The farther we get into the year the greater the risk patients, particularly new patients, won’t be able to secure assistance. With only 25% of disease funds open now, what will the situation be in 3 months? In 6 months? This is reality for far too many PAH and other rare disease patients. #pah #rarediseases #medicare #patientsfirst #access #janssen

Novel Insulin Therapy available at a clinic near you! 

🎉 Exciting breakthrough in PAH treatment: FDA approves WINREVAIR! 🎉 @Merck has just received the green light from the FDA for WINREVAIR, fantastic news for adults battling Pulmonary Arterial Hypertension (PAH). Let's break it down: 😍 Innovative Therapy: It's the first of its kind, targeting a brand-new pathway in PAH treatment. Just imagine.... opening a new door to better breathing and heart health!!!!! 🏃♂️ Boosted Exercise Capacity: Patients can look forward to not just walking further but feeling better. SIGNIFICANTLY improving exercise ability. 🚀 Rapid Improvements: Alongside standard treatments, it dramatically enhances quality of life, reducing risks of disease progression. 💡 Safety Checks: Regular monitoring ensures that treatment with WINREVAIR stays on the safe side, focusing on hemoglobin and platelet counts. Keep an eye out - it's hitting specialty pharmacies by the end of April! #PAH #WINREVAIR #HealthcareInnovation #FDAApproval #Merck